» Articles » PMID: 16371857

Using Audiometric Thresholds and Word Recognition in a Treatment Study

Overview
Journal Otol Neurotol
Date 2005 Dec 24
PMID 16371857
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: First, to examine a possible limit on significant results imposed by a progressive floor effect for hearing threshold improvement in a treatment study. This floor effect for hearing recovery suggests that if inclusion criteria are not set sufficiently high, the superiority of a treatment group may not be detectable. Second, to examine the outcomes when using two different types of criteria for significant change in a subject's word recognition score.

Methods: Several single-number criteria (e.g., 15 percentage points) are compared with the 95% (p=0.05) criteria from the binomial critical difference table for monosyllables. Critical differences for binomial variables change depending on whether the starting value lies in the middle (near 50% correct) or at either extreme of the range of scores (0 or 100%). Different judgments of significant word recognition improvement (or decrease) using binomial versus single-value criteria are presented.

Data Source: A recent treatment study of sudden sensorineural hearing loss (n=318) is used to illustrate these effects.

Conclusion: First, there is a progressive floor effect of presenting severity that co-varies with the outcome measure hearing threshold recovery. In some designs, this may act to constrain the ability to detect a significant difference. Second, in the example data set, the use of single-value criteria for significant within-subject change in word recognition (e.g., 15 percentage points) introduced a miscategorization error rate of approximately 9% when compared with the result of the binomial 95% critical difference table.

Citing Articles

N-Acetylcysteine combined with prednisolone treatment shows better hearing outcome than treatment with prednisolone alone for patients with idiopathic sudden sensorineural hearing loss: a retrospective observational study.

Kouka M, Bevern N, Bitter J, Guntinas-Lichius O Eur Arch Otorhinolaryngol. 2023; 281(1):107-116.

PMID: 37392235 PMC: 10764364. DOI: 10.1007/s00405-023-08097-4.


Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.

Plotkin S, Allen J, Dhall G, Campian J, Clapp D, Fisher M Neuro Oncol. 2023; 25(8):1498-1506.

PMID: 37010875 PMC: 10398799. DOI: 10.1093/neuonc/noad066.


Accelerated Long-Term Hearing Loss Progression After Recovery From Idiopathic Sudden Sensorineural Hearing Loss.

Early S, van der Valk J, Frijns J, Stankovic K Front Neurol. 2021; 12:738942.

PMID: 34956043 PMC: 8693444. DOI: 10.3389/fneur.2021.738942.


Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.

Wu L, Vasilijic S, Sun Y, Chen J, Landegger L, Zhang Y Sci Transl Med. 2021; 13(602).

PMID: 34261799 PMC: 8409338. DOI: 10.1126/scitranslmed.abd4816.


Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma.

Early S, Rinnooy Kan C, Eggink M, Frijns J, Stankovic K Front Neurol. 2020; 11:796.

PMID: 33013614 PMC: 7461819. DOI: 10.3389/fneur.2020.00796.